company background image
POLX.F logo

Polydex Pharmaceuticals OTCPK:POLX.F Stock Report

Last Price

US$1.99

Market Cap

US$6.8m

7D

0.3%

1Y

175.8%

Updated

07 Aug, 2023

Data

Company Financials

Polydex Pharmaceuticals Limited

OTCPK:POLX.F Stock Report

Market Cap: US$6.8m

POLX.F Stock Overview

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide.

POLX.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Polydex Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Polydex Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.99
52 Week HighUS$2.01
52 Week LowUS$0.55
Beta0.45
1 Month Change-1.19%
3 Month Change6.20%
1 Year Change175.83%
3 Year Change130.93%
5 Year Change89.14%
Change since IPO-90.37%

Recent News & Updates

Recent updates

Shareholder Returns

POLX.FUS PharmaceuticalsUS Market
7D0.3%-0.2%0.6%
1Y175.8%23.9%29.5%

Return vs Industry: POLX.F exceeded the US Pharmaceuticals industry which returned -4.4% over the past year.

Return vs Market: POLX.F exceeded the US Market which returned 15.2% over the past year.

Price Volatility

Is POLX.F's price volatile compared to industry and market?
POLX.F volatility
POLX.F Average Weekly Movement6.1%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: POLX.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine POLX.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
197920George Usherhttps://www.polydex.com

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry.

Polydex Pharmaceuticals Limited Fundamentals Summary

How do Polydex Pharmaceuticals's earnings and revenue compare to its market cap?
POLX.F fundamental statistics
Market capUS$6.82m
Earnings (TTM)-US$842.27k
Revenue (TTM)US$4.74m

1.4x

P/S Ratio

-8.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
POLX.F income statement (TTM)
RevenueUS$4.74m
Cost of RevenueUS$4.60m
Gross ProfitUS$142.86k
Other ExpensesUS$985.13k
Earnings-US$842.27k

Last Reported Earnings

Apr 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.25
Gross Margin3.01%
Net Profit Margin-17.76%
Debt/Equity Ratio2.8%

How did POLX.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.